Abstract
Bladder cancer (BC) is the ninth most commonly diagnosed malignant tumour in the world, with an incidence of about 356,000 and a mortality of about 145,000 per year in both non-muscle-invasive and muscle-invasive BC. Although a high percentage of urothelial cancers of the bladder are staged as non- muscle-invasive, muscle invasion can already be found in about 30% of all patients at the time of initial diagnosis. The intention of the following article is to give an overview of the diagnosis and treatment of muscle-invasive and metastatic BC according to the latest update of the EAU (European Association of Urology) guidelines.
Please view the full content in the pdf above.
